Renal Insufficiency, Chronic
Recent clinical, regulatory, research and industry developments relating to this disease.
Gut microbiota regulates oxidative stress and inflammation: a double-edged sword in renal fibrosis.
Glucagon-like peptide-1 receptor agonists and kidney outcomes.
Chronic kidney disease and the global public health agenda: an international consensus.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q2 2027.
- Active recent publication activity.
Research HighlightsViewHide
Clinical MilestonesViewHide
- 2026-06-09DOVIMIR : Multi-parametric MRI Evaluation of Renal Graft Performance After Living Donor DonationResults expected Q3 2029
- 2026-05-18Neurovascular Regulation During Exercise in Humans With Chronic Kidney DiseaseResults expected Q2 2027
- 2026-06-09ClinicalDOVIMIR : Multi-parametric MRI Evaluation of Renal Graft Performance After Living Donor DonationResults expected Q3 2029
- 2026-05-18ClinicalNeurovascular Regulation During Exercise in Humans With Chronic Kidney DiseaseResults expected Q2 2027
- 2025-10-03ClinicalEffects of Probiotic Supplementation on Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease: A Randomized Controlled TrialPrimary completion
- 2025-09-08ResearchToxic microbiome and progression of chronic kidney disease: insights from a longitudinal CKD-Microbiome Study.Laiola M · 2025
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and… (2007)
Approval — Infants, children and adolescents Growth disturbance due to insufficient secretion of gr… (2006)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Renal Insufficiency, Chronic37
- Cardiovascular Diseases12
- Diabetes Mellitus, Type 211
- Gastrointestinal Microbiome6
- Diabetes Mellitus5
- Sodium-Glucose Transporter 2 Inhibitors5
- Heart Failure4
- Acute Kidney Injury3
Leading journals6
- Nature reviews. Nephrology7
- Kidney international5
- Circulation3
- Frontiers in immunology3
- International journal of molecular sciences3
- Nature reviews. Disease primers3
Leading researchers8
- Rossing P7
- Heerspink HJL5
- Anker SD4
- Claggett BL4
- Perkovic V4
- Solomon SD4
- Tonelli M4
- Vaduganathan M4
Affiliations (unnormalised)6
- Brigham and Women's Hospital5
- University of Texas Southwestern Medical Center4
- Department of Clinical Medicine3
- Department of Clinical Pharmacy and Pharmacology3
- Ghent University Hospital3
- Steno Diabetes Center Copenhagen3
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Chronic renal insufficiency is a condition in which the kidneys function below normal for more than three months. It is staged by the degree of decline in glomerular filtration rate and by kidney damage such as proteinuria, with end-stage renal disease representing the most severe form.
The supplied grounding does not identify a single cause for chronic renal insufficiency. It is described as a chronic disease state that can arise in the context of diabetes, hypertension, ageing-related nephron loss, or as a continuum following acute kidney injury.
The disease is characterized by persistent reduction in kidney function, reflected by declining glomerular filtration rate and kidney damage such as proteinuria. The literature grounding also links chronic kidney disease to irreversible loss of kidney cells and nephrons, and to broader physiopathologic processes involving oxidative stress, immunity, cytokines, and the gastrointestinal microbiome.
Diabetes, hypertension, and ageing-related nephron loss are identified in the grounding as contributors to chronic kidney disease. The literature also notes that chronic kidney disease is an independent risk factor for cardiovascular disease and is associated with increased cardiovascular morbidity, premature mortality, and reduced quality of life.
Management is described at the level of broad therapeutic classes and supportive measures rather than specific regimens. The grounding supports blood glucose control, blood pressure control, blockade of the renin-angiotensin-aldosterone system, and use of SGLT2 inhibitors in patients with type 2 diabetes; it also includes finerenone and semaglutide among co-studied therapies, along with diet, exercise, and synbiotics.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.